TNToshihiro Nukiwa

Toshihiro Nukiwa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Toshihiro Nukiwa has a total of 82 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Real-World Safety, Tolerability and Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Final Report of Post-marketing Surveillance in Japan

    by Yoshikazu Inoue, Takashi Ogura, Arata Azuma, Yasuhiro Kondoh, Sakae Homma, Kenya Muraishi, Rie Ikeda, Kaori Ochiai, Yukihiko Sugiyama, Toshihiro Nukiwa

    Introduction Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrotic interstitial pneumonia, which is characterised by progressive worsening of dyspnoea and lung function. Nintedanib treatment is recommended to slow IPF disease progression. The aim of this post-marketing surveillance (PMS) study was to evaluate the safety and effectiveness of nintedanib over 24 months in patients with IPF in a real-world setting in Japan. Methods This prospective, non-interventional, all-case PMS study of nintedanib included Japanese patients with IPF who started nintedanib between 7 October 2015 and 2 May 2023. The primary outcome was to determine the proportion of patients with adverse drug reactions (ADRs), and the secondary outcome was the adjusted absolute change from baseline in forced vital capacity (FVC) at 24 months. Results In total, 5717 patients from 1013 institutions were included in the safety analysis (mean ± standard deviation age 71.7 ± 8.1 years, 78.1% male, 70.8% current or former smokers). Most patients (83.9%) had initiated nintedanib at a dose of 150 mg capsules twice daily. At 24 months, 2841 patients (64.8%) had discontinued nintedanib, mainly due to adverse events (44.0%), ADRs (24.1%) or insufficient effectiveness (5.7%). The most common ADRs were diarrhoea (35.5%), hepatic function abnormal (14.4%), decreased appetite (9.9%), liver disorders (7.8%) and nausea (5.8%). The adjusted absolute mean change in FVC from baseline to 24 months was − 212.3 mL (95% confidence interval − 235.3, − 189.3). Conclusion This is the largest prospective study to investigate patients with IPF who were treated with nintedanib. The safety and effectiveness of nintedanib treatment in this real-world setting of Japanese patients with IPF was similar to that reported in previous studies. Nintedanib effectively slowed the progression of IPF. No new safety concerns were identified, and the need for appropriate management of hepatic disorders and diarrhoea (as per the approved product information) was confirmed. Study Registration ClinicalTrials.gov (NCT02607722)/European Union electronic register of Post-Authorisation Studies (EUPAS10891).


  • Open Access

    Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan

    by Takashi Ogura, Yoshikazu Inoue, Arata Azuma, Sakae Homma, Yasuhiro Kondoh, Katsumi Tanaka, Kaori Ochiai, Yukihiko Sugiyama, Toshihiro Nukiwa

    Introduction Nintedanib is recommended for the treatment of idiopathic pulmonary fibrosis (IPF); however, treatment discontinuation due to adverse events (AEs) is common. A large-scale post-marketing surveillance study is investigating the real-world tolerability/safety of nintedanib in Japanese patients with IPF in routine clinical practice. Here, we report a 12-month interim analysis of this study. Methods The study included Japanese patients with IPF who started nintedanib between 31 August 2015 and 25 December 2018. The primary outcome was the frequency of adverse drug reactions (ADRs), defined as AEs for which a causal relationship with nintedanib could not be excluded. The secondary outcome was change from baseline in forced vital capacity (FVC). Outcomes were analysed in patients who stopped (‘discontinued’ subgroup) and continued (‘continued’ subgroup) nintedanib after 12 months. A multivariate analysis was performed to determine potential risk factors for treatment discontinuation. Results Of 5578 patients in the safety analysis set, 2795 (50.1%) discontinued nintedanib within 12 months of treatment initiation. Overall, 3767 patients (67.5%) had ADRs, with 1356 (24.3%) discontinuing nintedanib because of an ADR. Among patients in the ‘discontinued’ subgroup (n = 2795), 1442 (51.6%) discontinued because of an ADR. The most common ADRs causing discontinuation within 3 and 12 months were hepatic function abnormal (n = 137/730; 18.8%) and diarrhoea (n = 190/1442; 13.2%), respectively. At 12 months, the decrease in FVC from baseline was smaller in the ‘continued’ versus the ‘discontinued’ subgroup (adjusted mean ± standard error change − 104.4 ± 10.9 ml vs. − 311.2 ± 29.2 ml). Stage III/IV IPF and FVC < 70% predicted at baseline were risk factors for early treatment discontinuation. Conclusion About 50% of Japanese patients with IPF discontinued nintedanib within the first year of treatment, with worse lung function being associated with an increased risk of early treatment discontinuation. Trial registration: ClinicalTrials.gov: NCT02607722; European Union electronic register of Post-Authorisation Studies: EUPAS10891.


  • Clinical significance of serum SP-D as a biomarker for antifibrotics in idiopathic pulmonary fibrosis (IPF): Post hoc analysis of a phase 3 trial of pirfenidone in Japan

    by Hirofumi Chiba, Kimiyuki Ikeda, Arata Azuma, Yasuhiro Kondoh, Takashi Ogura, Yoshio Taguchi, Masahito Ebina, Shogo Miyazawa, Hiroki Sakaguchi, Moritaka Suga, et al.

    Background: The heterogeneity in IPF poses a major challenge for management of IPF. Antifibrotic drugs suppress the disease progression, and they also improve the survival in some patients. However, no biomarker has been proved to predict the response to antifibrotics. Aims and Objectives: We evaluated the significance of serum markers as predictor for response to pirfenidone in patients in phase 3 trial in Japan. Methods: We analyzed the data from 267 patients with IPF in phase 3 trial of pirfenidone in Japan. Association of baseline serum SP-D levels was examined with changes from baseline in vital capacity (VC) and progression-free survival (PFS: the progression was defined as a ≥10% decline in VC from baseline and/or death). Results: When patients were divided into high and low SP-D groups by the median level at baseline (202 ng/mL), significantly better response (changes in VC at 52 weeks and PFS) to pirfenidone was observed in low SP-D group than in high SP-D group (Figure). Serum concentration of SP-D decreased during therapeutic course in pirfenidone groups, and the decline was significant from 8 weeks after the initiation of pirfenidone. Conclusions: Serum SP-D levels has the potential for a predictor of response to pirfenidone in patients with IPF, and for a biomarker to monitor the course of treatment.


  • Risk factors for acute exacerbation of idiopathic pulmonary fibrosis – Extended analysis of pirfenidone trial in Japan

    by Yasuhiro Kondoh, Hiroyuki Taniguchi, Masahito Ebina, Arata Azuma, Takashi Ogura, Yoshio Taguchi, Moritaka Suga, Hiroki Takahashi, Koichiro Nakata, Yukihiko Sugiyama, et al.


  • Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: Extended analysis of phase III trial in Japan

    by Yoshio Taguchi, Masahito Ebina, Seishu Hashimoto, Takashi Ogura, Arata Azuma, Hiroyuki Taniguchi, Yasuhiro Kondoh, Moritaka Suga, Hiroki Takahashi, Koichiro Nakata, et al.


  • All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis

    by Takashi Ogura, Arata Azuma, Yoshikazu Inoue, Hiroyuki Taniguchi, Kingo Chida, Masashi Bando, Yuka Niimi, Shinichi Kakutani, Moritaka Suga, Yukihiko Sugiyama, et al.


  • A prospective survey of idiopathic interstitial pneumonias in a web registry in Japan

    by Masashi Bando, Yukihiko Sugiyama, Arata Azuma, Masahito Ebina, Hiroyuki Taniguchi, Yoshio Taguchi, Hiroki Takahashi, Sakae Homma, Toshihiro Nukiwa, Shoji Kudoh


  • Current status and future perspectives of cooperative study groups for lung cancer in Japan

    by Yuko Kawano, Isamu Okamoto, Haruhiko Fukuda, Yuichiro Ohe, Shinichiro Nakamura, Kazuhiko Nakagawa, Katsuyuki Hotta, Katsuyuki Kiura, Yuichi Takiguchi, Hideo Saka, et al.


  • Additional treatment with clarithromycin reduces fever duration in patients with influenza

    by Fuyuhiko Higashi, Hiroshi Kubo, Hiroyasu Yasuda, Toshihiro Nukiwa, Mutsuo Yamaya


  • Open Access

    Double-blind controlled trial of lecithinized superoxide dismutase in patients with idiopathic interstitial pneumonia – short term evaluation of safety and tolerability

    by Koichiro Kamio, Arata Azuma, Ken Ohta, Yukihiko Sugiyama, Toshihiro Nukiwa, Shoji Kudoh, Tohru Mizushima

    Background: Idiopathic interstitial pneumonias such as idiopathic pulmonary fibrosis or fibrotic nonspecific interstitial pneumonia are irreversible progressive pulmonary diseases that often have fatal outcomes. Although the etiology of idiopathic interstitial pneumonias is not yet fully understood, anti-fibrotic and anti-inflammatory agents have shown limited therapeutic effectiveness. Reactive oxygen species and their cytotoxic effects on the lung epithelial cells have been reported to participate in the pathophysiology of the disease. Because superoxide dismutase catalyzes the detoxification of reactive oxygen species, we developed lecithinized superoxide dismutase for the treatment of patients with idiopathic interstitial pneumonias.Methods: A multicenter, randomized, placebo-controlled trial was conducted as a pilot study to investigate the safety and effectiveness of 40 or 80 mg lecithinized superoxide dismutase in patients with progressive idiopathic interstitial pneumonias who presented with either idiopathic pulmonary fibrosis or corticosteroid-resistant fibrotic nonspecific interstitial pneumonia and showed arterial oxygen tension compatible with stage III or IV on the Japanese severity grading scale for idiopathic interstitial pneumonias. Before and following infusion of lecithinized superoxide dismutase for 28 days, the primary endpoint of forced vital capacity and the secondary endpoints of lactate dehydrogenase, surfactant protein-A, surfactant protein-D and Krebs von den Lungen-6 levels were measured in the serum.Results: The primary endpoint of forced vital capacity did not improve significantly in the lecithinized superoxide dismutase groups in comparison with the placebo group. The secondary endpoints of lactate dehydrogenase and surfactant protein-A levels were significantly attenuated by 28 days in the higher-dose (80 mg) group. However, these changes returned to the baseline levels by 56 days after the cessation of lecithinized superoxide dismutase. Adverse events and mortality in the drug-treated groups did not differ from those in the placebo group.Conclusions: Treatment with lecithinized superoxide dismutase is safe and improves the levels of serum markers such as lactate dehydrogenase and surfactant protein-A in patients with advanced idiopathic interstitial pneumonias with severe respiratory dysfunction. Considering the results of the current study, further investigations into the effects and treatment potential of long-term administration of lecithinized superoxide dismutase may be warranted.Trial registration: University hospital Medical Information Network (UMIN) clinical trials registry no.000000752